MONTREAL, QC--(Marketwired - October 17, 2016) - Angiochem, a biotechnology company developing peptide-drug conjugates uniquely capable of crossing the blood-brain barrier, recently presented data from its Phase II trial for its lead compound, ANG1005, at two highly regarded international cancer conferences: The European Society for Medical Oncology (ESMO) 2016 Congress and the European Association of Neuro-Oncology (EANO) 2016 Meeting.
On Friday Oct 7th, 2016 at the ESMO Congress, Copenhagen, Denmark, Shou-Ching Tang, MD, PhD Leader, Breast Cancer Multidisciplinary Program, Augusta University, Augusta, GA, USA presented a podium presentation titled: ANG1005, a novel peptide-paclitaxel conjugate crosses the BBB and shows activity in patients with recurrent CNS metastasis from breast cancer, results from a phase II clinical study.
In this report of the multi-center, open label Phase II trial ANG1005-CLN-04, ANG1005 demonstrated clinical benefit, both intracranially and extracranially in pretreated breast cancer patients with recurrent brain metastases.
The data on those patients enrolled in ANG1005-CLN-04 who had leptomeningeal carcinomatosis (LC) as well as recurrent breast cancer brain metastasis was updated at the 12th EANO Meeting, Mannheim, Germany. On Sunday, October 16, 2016, Priya Kumthekar, MD Director of the Brain Metastasis Program, Northwestern University, Chicago, IL, USA presented a podium presentation titled: A phase II study of ANG1005, a novel BBB/BCB penetrant taxane in patients with recurrent brain metastases and leptomeningeal carcinomatosis from breast cancer.
"Our data suggests that ANG1005 is active against previously-treated breast cancer metastasis both within and outside the central nervous system," said presenter Dr. Priya Kumthekar. "As a result, we believe this compound has strong potential to treat relapsed BCBM patients, particularly those recently diagnosed with leptomeningeal carcinomatosis (LC)."
Patients with BCBM and LC also showed improved clinical symptoms and increased overall survival compared to historical control groups. Safety for ANG1005 was similar to that of Paclitaxel.
"This compound shows strong potential to treat a patient population that has few alternative treatment options. As such, advancing this compound clinically remains our top priority," said John Huss, Executive Chairman of Angiochem. "We look forward to completing the final preparatory stages before starting our Phase III trial in the new year."
ANG1005 is a peptide-drug conjugate containing paclitaxel covalently linked to a peptide (Angiopep-2) designed to cross the blood-brain barrier (BBB) and blood cerebrospinal fluid barrier (BCB) via the LRP-1 transport system.
Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.
Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit http://www.angiochem.com.